Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Biopharma Driving Surge in Contract Pharmaceutical Manufacturing

By LabMedica International staff writers
Posted on 12 Mar 2009
The pharmaceutical manufacturing industry is evolving as new technologies such as biologics and sterile manufacturing take over, requiring specialized production and processes, according to a new market report. More...


The sheer numbers of biologics in the pipeline are impelling drug makers to outsource specialized production rather than build new plants. Medical market research publisher Kalorama Information (New York, NY, USA), a market research company, estimates the market for contract manufacturing of prescription drugs will exceed US$30 billion in 2008, which represents an increase of 10% from the prior year, which represents an increase of 10% from the prior year.

The two fastest growing sectors in the contract manufacturing market are biomanufacturing and secondary manufacturing, according to market analyst from Kalorama. The expansion of biotech-derived protein and peptide drugs, antibiotics, and chemotherapeutic agents administered as sterile injectable drugs is creating a robust business for sterile secondary contract manufacturing, as these processes are often not included in the core competency of pharmaceutical and biotech drug makers.

While the primary contract manufacturing organization (CMO) sector, which includes active pharmaceutical ingredients and chemical intermediates, is plagued by overcapacity, reduced drug output, and a highly competitive landscape, the secondary CMO sector is enjoying strong growth, due in large part to the great demand for sterile manufacturing. As a result, many CMOs are expanding their capabilities to include biopharmaceutical facilities. They are also turning to smaller emerging drug companies for new business and must, therefore, change their business model, as their needs are different and they outsource many activities major drug companies do internally, according to at Kalorama market analysts.

"Cost is important, but so are speed and flexibility,” said Bruce Carlson, publisher of Kalorama Information. "Pharma companies that want to pursue specialized niches, complicated drug delivery, and/or biologic drugs will have to contact a CRO [contract research organization].”

Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of research services.

Related Links:

Kalorama Information




Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.